Concepts (76)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Treatment Refusal | 2 | 2015 | 20 | 1.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 95 | 0.870 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 413 | 0.830 |
Why?
|
| Hospitals, General | 1 | 2015 | 7 | 0.560 |
Why?
|
| Insurance Coverage | 1 | 2015 | 99 | 0.530 |
Why?
|
| Thiocarbamates | 1 | 2014 | 4 | 0.510 |
Why?
|
| Length of Stay | 1 | 2015 | 184 | 0.510 |
Why?
|
| Androstadienes | 1 | 2014 | 18 | 0.510 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 794 | 0.510 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 114 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 178 | 0.470 |
Why?
|
| Patient Dropouts | 1 | 2013 | 26 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 531 | 0.400 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1426 | 0.370 |
Why?
|
| Mental Disorders | 1 | 2013 | 285 | 0.350 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 292 | 0.320 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 685 | 0.270 |
Why?
|
| United States | 6 | 2023 | 3894 | 0.270 |
Why?
|
| Mass Screening | 3 | 2023 | 427 | 0.260 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 2333 | 0.250 |
Why?
|
| Aged | 7 | 2022 | 6448 | 0.250 |
Why?
|
| Health Care Surveys | 2 | 2015 | 136 | 0.250 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 18 | 0.250 |
Why?
|
| Patient Discharge | 2 | 2015 | 92 | 0.240 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1349 | 0.230 |
Why?
|
| Humans | 13 | 2023 | 34853 | 0.210 |
Why?
|
| Communication | 1 | 2023 | 170 | 0.210 |
Why?
|
| Sex Factors | 2 | 2015 | 859 | 0.200 |
Why?
|
| Decision Making | 1 | 2023 | 189 | 0.200 |
Why?
|
| Young Adult | 3 | 2015 | 4012 | 0.190 |
Why?
|
| Female | 9 | 2022 | 19873 | 0.190 |
Why?
|
| Adolescent | 3 | 2015 | 5035 | 0.180 |
Why?
|
| Middle Aged | 5 | 2023 | 9642 | 0.180 |
Why?
|
| Male | 5 | 2023 | 18870 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 142 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2018 | 322 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 31 | 0.170 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 122 | 0.150 |
Why?
|
| Adult | 4 | 2022 | 11034 | 0.150 |
Why?
|
| Hormones | 1 | 2015 | 51 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2022 | 1961 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 423 | 0.130 |
Why?
|
| Sirolimus | 1 | 2014 | 58 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 78 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 145 | 0.120 |
Why?
|
| Urban Population | 1 | 2015 | 318 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2013 | 49 | 0.110 |
Why?
|
| Logistic Models | 1 | 2015 | 894 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2015 | 301 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 1003 | 0.100 |
Why?
|
| Medicaid | 1 | 2013 | 102 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2013 | 202 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 775 | 0.100 |
Why?
|
| Age Factors | 1 | 2013 | 1007 | 0.090 |
Why?
|
| Obesity | 1 | 2015 | 965 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 628 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 790 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 51 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 233 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2023 | 311 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 188 | 0.050 |
Why?
|
| Focus Groups | 1 | 2021 | 307 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 348 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 16 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 537 | 0.040 |
Why?
|
| Propensity Score | 1 | 2016 | 40 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 41 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 142 | 0.040 |
Why?
|
| Vinblastine | 1 | 2015 | 9 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 22 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 18 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 36 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 269 | 0.030 |
Why?
|
| Social Class | 1 | 2015 | 228 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 288 | 0.030 |
Why?
|
| Exercise | 1 | 2015 | 524 | 0.020 |
Why?
|